Systemic capsaicin for burning mouth syndrome: short-term results of a pilot study
Background: Burning mouth syndrome (BMS) is a major diagnostic and therapeutic problem. Systemic and topical treatments (capsaicin, lidocaine, anti‐histamines, sucralfate and benzydiamine) have been tried, but they appear to be inadequate. Topical capsaicin is bitter, may cause burning and has low...
Saved in:
Published in | Journal of oral pathology & medicine Vol. 33; no. 2; pp. 111 - 114 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Oxford, UK
Munksgaard International Publishers
01.02.2004
Blackwell |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Background: Burning mouth syndrome (BMS) is a major diagnostic and therapeutic problem. Systemic and topical treatments (capsaicin, lidocaine, anti‐histamines, sucralfate and benzydiamine) have been tried, but they appear to be inadequate. Topical capsaicin is bitter, may cause burning and has low therapeutic efficacy. We hypothesized that systemic administration of capsaicin could reduce the limitations of topical administration and have better therapeutic efficacy; this hypothesis was tested in a controlled trial.
Methods: Systemic oral capsaicin 0.25% was used for patients with BMS, recruited in our single centre. After the diagnosis of BMS, patients were dentally and medically examined. They were alternatively assigned to treatment with capsaicin or to a shape/smell/taste/color matched placebo. The severity of symptoms was scored at trial entry and 30 days thereafter by investigators who were unaware of the assigned intervention. The visual analogical scale (VAS) measure was used to score the severity of pain, and results for the treated and untreated groups were compared by Fisher's exact test. Analysis was performed by intention‐to‐treat. Statistical significance was considered for values of P < 0.05. Data are expressed as mean ± SD.
Results: Fifty patients were enrolled (25 assigned to systemic capsaicin and 25 to placebo). The VAS score was significantly lower in treated patients (5.84 ± 1.17) as compared to the placebo‐control group (6.24 ± 0.96). The use of systemic capsaicin implied significant gastric toxicity (referred gastric pain) with eight cases (32%) documented in the treatment group as compared to zero cases (0%) in the placebo control group.
Conclusion: Systemic capsaicin is therapeutically effective for the short‐term treatment of BMS but major gastrointestinal side‐effects may threaten its large‐scale, long‐term use. This preliminary study suggests that more, adequately powered, randomized controlled trials are necessary and worthy to come to a definitive assessment of this matter. |
---|---|
AbstractList | Burning mouth syndrome (BMS) is a major diagnostic and therapeutic problem. Systemic and topical treatments (capsaicin, lidocaine, anti-histamines, sucralfate and benzydiamine) have been tried, but they appear to be inadequate. Topical capsaicin is bitter, may cause burning and has low therapeutic efficacy. We hypothesized that systemic administration of capsaicin could reduce the limitations of topical administration and have better therapeutic efficacy; this hypothesis was tested in a controlled trial.
Systemic oral capsaicin 0.25% was used for patients with BMS, recruited in our single centre. After the diagnosis of BMS, patients were dentally and medically examined. They were alternatively assigned to treatment with capsaicin or to a shape/smell/taste/color matched placebo. The severity of symptoms was scored at trial entry and 30 days thereafter by investigators who were unaware of the assigned intervention. The visual analogical scale (VAS) measure was used to score the severity of pain, and results for the treated and untreated groups were compared by Fisher's exact test. Analysis was performed by intention-to-treat. Statistical significance was considered for values of P < 0.05. Data are expressed as mean +/- SD.
Fifty patients were enrolled (25 assigned to systemic capsaicin and 25 to placebo). The VAS score was significantly lower in treated patients (5.84 +/- 1.17) as compared to the placebo-control group (6.24 +/- 0.96). The use of systemic capsaicin implied significant gastric toxicity (referred gastric pain) with eight cases (32%) documented in the treatment group as compared to zero cases (0%) in the placebo control group.
Systemic capsaicin is therapeutically effective for the short-term treatment of BMS but major gastrointestinal side-effects may threaten its large-scale, long-term use. This preliminary study suggests that more, adequately powered, randomized controlled trials are necessary and worthy to come to a definitive assessment of this matter. Background: Burning mouth syndrome (BMS) is a major diagnostic and therapeutic problem. Systemic and topical treatments (capsaicin, lidocaine, anti‐histamines, sucralfate and benzydiamine) have been tried, but they appear to be inadequate. Topical capsaicin is bitter, may cause burning and has low therapeutic efficacy. We hypothesized that systemic administration of capsaicin could reduce the limitations of topical administration and have better therapeutic efficacy; this hypothesis was tested in a controlled trial. Methods: Systemic oral capsaicin 0.25% was used for patients with BMS, recruited in our single centre. After the diagnosis of BMS, patients were dentally and medically examined. They were alternatively assigned to treatment with capsaicin or to a shape/smell/taste/color matched placebo. The severity of symptoms was scored at trial entry and 30 days thereafter by investigators who were unaware of the assigned intervention. The visual analogical scale (VAS) measure was used to score the severity of pain, and results for the treated and untreated groups were compared by Fisher's exact test. Analysis was performed by intention‐to‐treat. Statistical significance was considered for values of P < 0.05. Data are expressed as mean ± SD. Results: Fifty patients were enrolled (25 assigned to systemic capsaicin and 25 to placebo). The VAS score was significantly lower in treated patients (5.84 ± 1.17) as compared to the placebo‐control group (6.24 ± 0.96). The use of systemic capsaicin implied significant gastric toxicity (referred gastric pain) with eight cases (32%) documented in the treatment group as compared to zero cases (0%) in the placebo control group. Conclusion: Systemic capsaicin is therapeutically effective for the short‐term treatment of BMS but major gastrointestinal side‐effects may threaten its large‐scale, long‐term use. This preliminary study suggests that more, adequately powered, randomized controlled trials are necessary and worthy to come to a definitive assessment of this matter. Background: Burning mouth syndrome (BMS) is a major diagnostic and therapeutic problem. Systemic and topical treatments (capsaicin, lidocaine, anti‐histamines, sucralfate and benzydiamine) have been tried, but they appear to be inadequate. Topical capsaicin is bitter, may cause burning and has low therapeutic efficacy. We hypothesized that systemic administration of capsaicin could reduce the limitations of topical administration and have better therapeutic efficacy; this hypothesis was tested in a controlled trial. Methods: Systemic oral capsaicin 0.25% was used for patients with BMS, recruited in our single centre. After the diagnosis of BMS, patients were dentally and medically examined. They were alternatively assigned to treatment with capsaicin or to a shape/smell/taste/color matched placebo. The severity of symptoms was scored at trial entry and 30 days thereafter by investigators who were unaware of the assigned intervention. The visual analogical scale (VAS) measure was used to score the severity of pain, and results for the treated and untreated groups were compared by Fisher's exact test. Analysis was performed by intention‐to‐treat. Statistical significance was considered for values of P < 0.05. Data are expressed as mean ± SD. Results: Fifty patients were enrolled (25 assigned to systemic capsaicin and 25 to placebo). The VAS score was significantly lower in treated patients (5.84 ± 1.17) as compared to the placebo‐control group (6.24 ± 0.96). The use of systemic capsaicin implied significant gastric toxicity (referred gastric pain) with eight cases (32%) documented in the treatment group as compared to zero cases (0%) in the placebo control group. Conclusion: Systemic capsaicin is therapeutically effective for the short‐term treatment of BMS but major gastrointestinal side‐effects may threaten its large‐scale, long‐term use. This preliminary study suggests that more, adequately powered, randomized controlled trials are necessary and worthy to come to a definitive assessment of this matter. |
Author | Serpico, Rosario Lauritano, Dorina Baldoni, Marco Petruzzi, Massimo De Benedittis, Michele |
Author_xml | – sequence: 1 givenname: Massimo surname: Petruzzi fullname: Petruzzi, Massimo organization: Department of Odontostomatology and Surgery, University of Bari, and – sequence: 2 givenname: Dorina surname: Lauritano fullname: Lauritano, Dorina organization: Department of Neurosciences, Unity of dentistry, University of Milan 'Bicocca', Italy – sequence: 3 givenname: Michele surname: De Benedittis fullname: De Benedittis, Michele organization: Department of Odontostomatology and Surgery, University of Bari, and – sequence: 4 givenname: Marco surname: Baldoni fullname: Baldoni, Marco organization: Department of Neurosciences, Unity of dentistry, University of Milan 'Bicocca', Italy – sequence: 5 givenname: Rosario surname: Serpico fullname: Serpico, Rosario organization: Department of Odontostomatology and Surgery, University of Bari, and |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15513441$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/14720197$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkV1LwzAUQIMoOj_-guTFx9Z7m3RtBR9EdCoyRac-hjRNNLMfI2lx_fd2buireUkg54TLyT7ZrptaE0IRQhzW6TzEMUAACfIwAuAhYMbrcLlFRr8X22QEGfAgijHaI_vezwEwYRx3yR7yJBqUZESennvf6soqquTCS6tsTU3jaN652tbvtGq69oP6vi5cU-kz6j8a1watdhV12ndl62ljqKQLWzYt9W1X9Idkx8jS66PNfkBerq9mlzfB_cPk9vLiPlA8zqaBMigNTyFDjZlOJKSFNlmuYyZ1KsFIUxilUyiAMTTZGMY8igoZKYZxnOucHZB0_a5yjfdOG7FwtpKuFwhilUnMxaqGWNUQq0ziJ5NYDurxWl10eaWLP3HTZQBONoD0SpbGyVpZ_8fFMTLOceDO19yXLXX_7wHE3cPjcJoOfrD27fALy19fuk8xTlgSi7fpRMxmr8_sLgHxxL4Bj9mWbw |
CitedBy_id | crossref_primary_10_1111_j_1601_0825_2012_01952_x crossref_primary_10_2217_pmt_11_35 crossref_primary_10_12968_npre_2007_5_6_24289 crossref_primary_10_1111_j_1600_0714_2010_00922_x crossref_primary_10_1007_s11916_008_0047_9 crossref_primary_10_3390_pharmaceutics13111838 crossref_primary_10_1016_j_adaj_2018_08_027 crossref_primary_10_1080_19424396_2007_12221241 crossref_primary_10_1111_jop_12101 crossref_primary_10_1016_j_coms_2012_11_001 crossref_primary_10_1177_03331024211036152 crossref_primary_10_1089_pho_2009_2630 crossref_primary_10_1136_flgastro_2014_100431 crossref_primary_10_1016_S0001_7310_08_74714_8 crossref_primary_10_1590_S0034_72992006000300021 crossref_primary_10_3342_kjorl_hns_2013_56_9_550 crossref_primary_10_1111_odi_13053 crossref_primary_10_1111_j_1600_0714_2008_00736_x crossref_primary_10_1016_S1578_2190_08_70287_7 crossref_primary_10_1016_j_jpsychores_2016_05_001 crossref_primary_10_1002_14651858_CD002779_pub3 crossref_primary_10_1590_1807_2577_00416 crossref_primary_10_1016_j_ajoms_2011_06_002 crossref_primary_10_1111_j_1365_2842_2006_01639_x crossref_primary_10_1016_j_ios_2010_11_004 crossref_primary_10_12968_denn_2012_8_11_717 crossref_primary_10_1093_bja_aet125 crossref_primary_10_3390_biomedicines10112680 crossref_primary_10_1016_j_tripleo_2006_11_009 crossref_primary_10_1111_j_1600_0714_2011_01100_x crossref_primary_10_3390_medicina57040391 crossref_primary_10_1111_odi_13067 crossref_primary_10_1016_j_brainres_2008_06_119 crossref_primary_10_18261_issn_2058_7538_2021_01_06 crossref_primary_10_5125_jkaoms_2024_50_2_63 crossref_primary_10_1007_s10103_012_1149_5 crossref_primary_10_4103_sjos_SJOralSci_69_20 crossref_primary_10_1016_j_piel_2010_03_017 crossref_primary_10_1111_ors_12542 crossref_primary_10_1111_j_1529_8019_2010_01325_x crossref_primary_10_1016_j_oooo_2017_01_005 crossref_primary_10_1016_j_pmn_2005_08_003 crossref_primary_10_1080_00016357_2016_1269191 crossref_primary_10_1111_joor_13102 crossref_primary_10_3342_kjorl_hns_2012_55_11_707 crossref_primary_10_1111_odi_12660 crossref_primary_10_1016_j_dentre_2022_100036 crossref_primary_10_1177_2515816320970143 crossref_primary_10_1111_j_1600_0528_2011_00645_x crossref_primary_10_1111_joor_12539 crossref_primary_10_1097_AAP_0b013e3182a1f0db crossref_primary_10_1016_S1808_8694_15_30979_4 crossref_primary_10_1016_j_coms_2007_12_012 crossref_primary_10_1111_odi_12422 crossref_primary_10_15557_AN_2023_0006 crossref_primary_10_1016_j_piel_2011_02_001 crossref_primary_10_1089_acm_2019_0478 crossref_primary_10_3390_biom11081237 crossref_primary_10_1111_odi_12192 crossref_primary_10_1515_jcim_2021_0434 crossref_primary_10_1016_j_recli_2013_09_001 crossref_primary_10_1111_j_1365_2842_2008_01914_x crossref_primary_10_3342_kjorl_hns_2019_00605 crossref_primary_10_1016_j_cacc_2008_07_003 |
Cites_doi | 10.1016/0885-3924(94)00130-D 10.1016/0030-4220(94)90275-5 10.1016/0304-3959(95)00089-B 10.1111/j.1600-0714.1999.tb02052.x 10.1016/S0022-3913(97)70089-1 10.1016/0030-4220(91)90162-6 10.1067/moe.2001.117452 10.1016/S1079-2104(99)70010-7 10.1016/0030-4220(92)90100-5 10.14219/jada.archive.1995.0305 10.1046/j.1440-1819.2002.00950.x 10.1016/S0304-3959(02)00052-0 10.1016/0030-4220(87)90336-7 10.1111/j.1600-0714.1993.tb00120.x |
ContentType | Journal Article |
Copyright | 2004 INIST-CNRS |
Copyright_xml | – notice: 2004 INIST-CNRS |
DBID | BSCLL IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION |
DOI | 10.1111/j.1600-0714.2004.0194n.x |
DatabaseName | Istex Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef |
DatabaseTitleList | MEDLINE CrossRef |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Dentistry |
EISSN | 1600-0714 |
EndPage | 114 |
ExternalDocumentID | 10_1111_j_1600_0714_2004_0194n_x 14720197 15513441 JOP194N ark_67375_WNG_TTVS3J70_R |
Genre | article Clinical Trial Randomized Controlled Trial Journal Article |
GroupedDBID | --- .3N .55 .GA .Y3 05W 0R~ 10A 1OB 1OC 29L 31~ 33P 34H 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAJUZ AAKAS AANLZ AAONW AASGY AAVGM AAWTL AAXRX AAZKR ABCQN ABCUV ABCVL ABEML ABHUG ABJNI ABLJU ABPTK ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACXBN ACXME ACXQS ADAWD ADBBV ADBTR ADDAD ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZCM ADZMN AEEZP AEIGN AEIMD AENEX AEQDE AEQTP AEUQT AEUYR AFBPY AFEBI AFFNX AFFPM AFGKR AFPWT AFVGU AFZJQ AGJLS AHBTC AHEFC AIACR AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ATUGU AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BSCLL BY8 C45 CAG COF CS3 CWXXS D-6 D-7 D-E D-F DC6 DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBD EBS EJD F00 F01 F04 F5P FEDTE FUBAC FZ0 G-S G.N GODZA H.X HF~ HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OVD P2P P2W P2X P2Z P4B P4D PALCI Q.N Q11 QB0 R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ TEORI UB1 UDS V8K W8V W99 WBKPD WBNRW WIH WIJ WIK WOHZO WPGGZ WQJ WRC WXI WXSBR X7M XG1 YFH YOC YUY ZGI ZXP ZZTAW ~IA ~WT AITYG HGLYW OIG AAUGY AKALU IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION |
ID | FETCH-LOGICAL-c459N-cf1af48091e19e7a08def9be53ae8a0fafdfce80d0331f9606422da2c3155beb3 |
IEDL.DBID | DR2 |
ISSN | 0904-2512 |
IngestDate | Fri Aug 23 00:54:47 EDT 2024 Sat Sep 28 07:39:30 EDT 2024 Sun Oct 22 16:05:47 EDT 2023 Sat Aug 24 01:05:57 EDT 2024 Wed Jan 17 05:01:50 EST 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | Human orofacial pain Oral cavity Pain Burning mouth syndrome stomatopyrosis Capsaicin Stomatology Oral cavity disease Face systemic capsaicin |
Language | English |
License | CC BY 4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c459N-cf1af48091e19e7a08def9be53ae8a0fafdfce80d0331f9606422da2c3155beb3 |
Notes | istex:8E43ED05F50C0F2CC6D3ABB4DE26A4D98F1BE9A2 ArticleID:JOP194N ark:/67375/WNG-TTVS3J70-R |
PMID | 14720197 |
PageCount | 4 |
ParticipantIDs | crossref_primary_10_1111_j_1600_0714_2004_0194n_x pubmed_primary_14720197 pascalfrancis_primary_15513441 wiley_primary_10_1111_j_1600_0714_2004_0194n_x_JOP194N istex_primary_ark_67375_WNG_TTVS3J70_R |
PublicationCentury | 2000 |
PublicationDate | February 2004 |
PublicationDateYYYYMMDD | 2004-02-01 |
PublicationDate_xml | – month: 02 year: 2004 text: February 2004 |
PublicationDecade | 2000 |
PublicationPlace | Oxford, UK |
PublicationPlace_xml | – name: Oxford, UK – name: Oxford – name: Denmark |
PublicationTitle | Journal of oral pathology & medicine |
PublicationTitleAlternate | J Oral Pathol Med |
PublicationYear | 2004 |
Publisher | Munksgaard International Publishers Blackwell |
Publisher_xml | – name: Munksgaard International Publishers – name: Blackwell |
References | Tammiala-Salonen T, Forssell H. Trazodone in burning mouth pain: a placebo-controlled, double-blind study. J Orofac Pain 1999; 13: 83-8. Sardella A, Uglietti D, Demarosi F, Lodi G, Bez C, Carrassi A. Benzydiamine hydrochloride oral rinses in management of burning mouth syndrome. A clinical trial. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999; 88: 683-6. Forabosco A, Criscuolo M, Coukos G, et al. Efficacy of hormone replacement therapy in postmenopausal women with oral discomfort. Oral Surg Oral Med Oral Pathol 1992; 73: 570-4. Ship JA, Grushka M, Lipton JA, Mott AE, Sessle BJ, Dionne RA. Burning mouth syndrome: an update. J Am Dent Assoc 1995; 126: 842-53. Ito M, Kurita K, Ito T, Arao M. Pain threshold and pain recovery after experimental stimulation in patients with burning mouth syndrome. Psychiatry Clin Neurosci 2002; 56: 161-8. Bergdahl J, Anneroth G. Burning Mouth syndrome: literature review and model for research and management. J Oral Pathol Med 1994; 22: 433-8. Gorsky M, Silverman S, Jr, Chinn H. Clinical characteristics and management outcome in the burning mouth syndrome. An open study of 130 patients. Oral Surg Oral Med Oral Pathol 1991; 72: 192-5. Cibirka RM, Nelson SK, Lefebvre CA. Burning mouth syndrome. a review of etiologies. J Prosthet Dent 1997; 78: 93-7. Epstein JB, Marcoe JH. Topical application of capsaicin for treatment of oral neuropathic pain and trigeminal neuralgia. Oral Surg Oral Med Oral Pathol 1994; 77: 135-40. Trombelli L, Zangari F, Calura G. The psychological aspects of patients with the burning mouth syndrome. Minerva Stomatol 1994; 43: 215-21. Berger A, Henderson M, Nadoolman W, et al. Oral capsaicin provides temporary relief for oral mucositis pain secondary to chemotherapy/radiation therapy. J Pain Symptom Manage 1995; 10: 243-8. Forssell H, Jaaskelainen S, Tenovuo O, Hinkka S. Sensory dysfunction in burning mouth syndrome. Pain 2002; 99: 41-7. Grushka M. Clinical features of burning mouth syndrome. Oral Surg Oral Med Oral Pathol 1987; 63: 30-6. Campisi G, Spadari F, Salvato A. Sucralfate in odontostomatology. Clinical experience. Minerva Stomatol 1997; 46: 297-305. Bergdahl M, Bergdahl J. Burning mouth syndrome: prevalence and associated factors. J Oral Pathol Med 1999; 28: 350-4. Buchanan J, Zakrzewska JM. The burning mouth syndrome remains an enigma. Pain 1995; 62: 253-7. Tarkkila L, Linna M, Tiitinen A, Lindqvist C, Meurman JH. Oral symptoms at menopause - the role of hormone replacement therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001; 92: 276-80. Rumsfield JA, West DP. Topical capsaicin in dermatologic and peripheral pain disorders. Ann Pharmacother 1991; 25: 381-7. Hersh EV, Pertes RA, Ochs HA. Topical capsaicin-pharmacology and potential role in the treatment of temporomandibular pain. J Clin Dent 1994; 5: 54-9. 2001; 92 1995; 62 1991; 25 1987; 63 1999; 28 2002; 56 1991; 72 1997; 46 1997; 78 1995; 10 2002; 99 1999; 13 1994; 77 1994; 22 1995; 126 1999; 88 1994; 5 1994; 43 1992; 73 e_1_2_5_14_2 Rumsfield JA (e_1_2_5_15_2) 1991; 25 e_1_2_5_9_2 e_1_2_5_16_2 e_1_2_5_8_2 e_1_2_5_6_2 e_1_2_5_5_2 Tammiala‐Salonen T (e_1_2_5_10_2) 1999; 13 e_1_2_5_12_2 e_1_2_5_20_2 e_1_2_5_4_2 e_1_2_5_11_2 e_1_2_5_3_2 Campisi G (e_1_2_5_13_2) 1997; 46 e_1_2_5_2_2 e_1_2_5_18_2 Hersh EV (e_1_2_5_17_2) 1994; 5 e_1_2_5_19_2 Trombelli L (e_1_2_5_7_2) 1994; 43 |
References_xml | – volume: 62 start-page: 253 year: 1995 end-page: 7 article-title: The burning mouth syndrome remains an enigma publication-title: Pain – volume: 5 start-page: 54 year: 1994 end-page: 9 article-title: Topical capsaicin‐pharmacology and potential role in the treatment of temporomandibular pain publication-title: J Clin Dent – volume: 43 start-page: 215 year: 1994 end-page: 21 article-title: The psychological aspects of patients with the burning mouth syndrome publication-title: Minerva Stomatol – volume: 73 start-page: 570 year: 1992 end-page: 4 article-title: Efficacy of hormone replacement therapy in postmenopausal women with oral discomfort publication-title: Oral Surg Oral Med Oral Pathol – volume: 46 start-page: 297 year: 1997 end-page: 305 article-title: Sucralfate in odontostomatology. Clinical experience publication-title: Minerva Stomatol – volume: 77 start-page: 135 year: 1994 end-page: 40 article-title: Topical application of capsaicin for treatment of oral neuropathic pain and trigeminal neuralgia publication-title: Oral Surg Oral Med Oral Pathol – volume: 25 start-page: 381 year: 1991 end-page: 7 article-title: Topical capsaicin in dermatologic and peripheral pain disorders publication-title: Ann Pharmacother – volume: 99 start-page: 41 year: 2002 end-page: 7 article-title: Sensory dysfunction in burning mouth syndrome publication-title: Pain – volume: 10 start-page: 243 year: 1995 end-page: 8 article-title: Oral capsaicin provides temporary relief for oral mucositis pain secondary to chemotherapy/radiation therapy publication-title: J Pain Symptom Manage – volume: 22 start-page: 433 year: 1994 end-page: 8 article-title: Burning Mouth syndrome: literature review and model for research and management publication-title: J Oral Pathol Med – volume: 88 start-page: 683 year: 1999 end-page: 6 article-title: Benzydiamine hydrochloride oral rinses in management of burning mouth syndrome. A clinical trial publication-title: Oral Surg Oral Med Oral Pathol Oral Radiol Endod – volume: 56 start-page: 161 year: 2002 end-page: 8 article-title: Pain threshold and pain recovery after experimental stimulation in patients with burning mouth syndrome publication-title: Psychiatry Clin Neurosci – volume: 78 start-page: 93 year: 1997 end-page: 7 article-title: Burning mouth syndrome. a review of etiologies publication-title: J Prosthet Dent – volume: 13 start-page: 83 year: 1999 end-page: 8 article-title: Trazodone in burning mouth pain: a placebo‐controlled, double‐blind study publication-title: J Orofac Pain – volume: 28 start-page: 350 year: 1999 end-page: 4 article-title: Burning mouth syndrome: prevalence and associated factors publication-title: J Oral Pathol Med – volume: 92 start-page: 276 year: 2001 end-page: 80 article-title: Oral symptoms at menopause – the role of hormone replacement therapy publication-title: Oral Surg Oral Med Oral Pathol Oral Radiol Endod – volume: 126 start-page: 842 year: 1995 end-page: 53 article-title: Burning mouth syndrome: an update publication-title: J Am Dent Assoc – volume: 63 start-page: 30 year: 1987 end-page: 6 article-title: Clinical features of burning mouth syndrome publication-title: Oral Surg Oral Med Oral Pathol – volume: 72 start-page: 192 year: 1991 end-page: 5 article-title: Clinical characteristics and management outcome in the burning mouth syndrome. An open study of 130 patients publication-title: Oral Surg Oral Med Oral Pathol – ident: e_1_2_5_18_2 doi: 10.1016/0885-3924(94)00130-D – ident: e_1_2_5_12_2 doi: 10.1016/0030-4220(94)90275-5 – volume: 25 start-page: 381 year: 1991 ident: e_1_2_5_15_2 article-title: Topical capsaicin in dermatologic and peripheral pain disorders publication-title: Ann Pharmacother contributor: fullname: Rumsfield JA – ident: e_1_2_5_5_2 doi: 10.1016/0304-3959(95)00089-B – ident: e_1_2_5_2_2 doi: 10.1111/j.1600-0714.1999.tb02052.x – ident: e_1_2_5_6_2 doi: 10.1016/S0022-3913(97)70089-1 – ident: e_1_2_5_8_2 doi: 10.1016/0030-4220(91)90162-6 – ident: e_1_2_5_11_2 doi: 10.1067/moe.2001.117452 – ident: e_1_2_5_14_2 doi: 10.1016/S1079-2104(99)70010-7 – volume: 5 start-page: 54 year: 1994 ident: e_1_2_5_17_2 article-title: Topical capsaicin‐pharmacology and potential role in the treatment of temporomandibular pain publication-title: J Clin Dent contributor: fullname: Hersh EV – ident: e_1_2_5_9_2 doi: 10.1016/0030-4220(92)90100-5 – ident: e_1_2_5_3_2 doi: 10.14219/jada.archive.1995.0305 – ident: e_1_2_5_19_2 doi: 10.1046/j.1440-1819.2002.00950.x – ident: e_1_2_5_20_2 doi: 10.1016/S0304-3959(02)00052-0 – ident: e_1_2_5_4_2 doi: 10.1016/0030-4220(87)90336-7 – volume: 46 start-page: 297 year: 1997 ident: e_1_2_5_13_2 article-title: Sucralfate in odontostomatology. Clinical experience publication-title: Minerva Stomatol contributor: fullname: Campisi G – volume: 43 start-page: 215 year: 1994 ident: e_1_2_5_7_2 article-title: The psychological aspects of patients with the burning mouth syndrome publication-title: Minerva Stomatol contributor: fullname: Trombelli L – ident: e_1_2_5_16_2 doi: 10.1111/j.1600-0714.1993.tb00120.x – volume: 13 start-page: 83 year: 1999 ident: e_1_2_5_10_2 article-title: Trazodone in burning mouth pain: a placebo‐controlled, double‐blind study publication-title: J Orofac Pain contributor: fullname: Tammiala‐Salonen T |
SSID | ssj0017341 |
Score | 2.077907 |
Snippet | Background: Burning mouth syndrome (BMS) is a major diagnostic and therapeutic problem. Systemic and topical treatments (capsaicin, lidocaine,... Burning mouth syndrome (BMS) is a major diagnostic and therapeutic problem. Systemic and topical treatments (capsaicin, lidocaine, anti-histamines, sucralfate... Background: Burning mouth syndrome (BMS) is a major diagnostic and therapeutic problem. Systemic and topical treatments (capsaicin, lidocaine,... |
SourceID | crossref pubmed pascalfrancis wiley istex |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 111 |
SubjectTerms | Administration, Oral Adult Aged Aged, 80 and over Analgesics, Non-Narcotic - administration & dosage Biological and medical sciences burning mouth syndrome Burning Mouth Syndrome - drug therapy Capsaicin - administration & dosage Double-Blind Method Female Humans Male Medical sciences Middle Aged orofacial pain Otorhinolaryngology. Stomatology Pain Measurement Pilot Projects stomatopyrosis systemic capsaicin Treatment Outcome |
Title | Systemic capsaicin for burning mouth syndrome: short-term results of a pilot study |
URI | https://api.istex.fr/ark:/67375/WNG-TTVS3J70-R/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1600-0714.2004.0194n.x https://www.ncbi.nlm.nih.gov/pubmed/14720197 |
Volume | 33 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3JbtswECWK9JBcumSr29TgIchNBmVRotVbkaWGD26QOMuNGHFBAqe2EclA0FM_od_YL-kMZTt20EMQ9CZAoCTOkJo35OMbxvYtguB2YVQUF9ZGMhcuAmVdZBAsiI4VtLVEbIt-1r2Qvev0esZ_orMwtT7EYsGNZkb4X9MEh6JcneQZnYpWcVgakS0EK3LUIjxJunqEj84WSlKxSkIRS5ELGVFIXyX1_PNBK5HqNRn9gZiTUKLxfF31YilsLUPbEJtO3rLhvFc1JWXYmlZFy_x8Ivj4f7r9jr2ZQVj-tR5z79krN9pk60dEO6LKcVtsUMug3xpuYFIC7d1zxMYc_UerMPwHle3jc62EL7y8wRzgz6_fFCU4pv_Tu6rkY8-BT27vxhUPErjb7OLkeHDYjWbVGyIj07wfGR-Dlx3EIy7OnQL0vPN54dIEXAeEB2-9cR1hRZLEnhIp2W5baJsEIU6BOf4OWxuNR-4D42kOkGWk02OcjAGo5iWYHH82mXVGqAaL557Sk1qkQy8lN2gvTfaikptSB3vphwY7CC5dNID7IZHcVKqv-t_0YHB5nvSU0GcN1lzx-eMbqDYOoskG260HweMdqRBX5fhdWXDlsz9K976f4lX_40sbfmIbNbWI-DZ7bK26n7rPiJqqohnmw1_SEgrp |
link.rule.ids | 315,786,790,1382,27955,27956,46327,46751 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9NAEF6h9lAuQHmGR9kD4uZoHa-9MTdEaUMoBhUXeluN9yGqhiSKHanixE_gN_aXdGadpAnigBA3S9bauzM7O9_Ozs7H2AuLILhXGRXFlbWRzIWLQFkXGQQLom8FHS1RtkWRDU7k8DQ9XdAB0V2Ytj7EKuBGlhHWazJwCkhvWnlG16JVHGIjsotoRY67CCi30fpTstL941UtqVglgcZS5EJG5NQ303r--KUNX7VNYr-g3EmoUXy-5b1Yc1zr4DZ4p4PbbLQcV5uUct6dN1XX_Pit5ON_GvgddmuBYvnrdtrtshtufJft7FPmEZHH3WNlWwn9zHAD0xro-J4jPOaoQgrE8O_E3MeX5RJe8fobbgMuf_4iR8Fnrp6PmppPPAc-PRtNGh6q4N5nJwdvyzeDaEHgEBmZ5kVkfAxe9hGSuDh3ClD5zueVSxNwfRAevPXG9YUVSRJ72kvJXs9CzySIcirc5j9gW-PJ2D1iPM0BsoxK9RgnYwCivQST43qTWWeE6rB4qSo9bet06LX9DcpLk7yIdVPqIC990WEvg05XDWB2TnluKtVfi0Ndll8-J0Ml9HGH7W0o_foPRI-DgLLDHraz4PqNVAitcuxXFnT5153Sw4-f8Kl4_K8Nn7OdQfnhSB-9K94_YTfbTCNKv3nKtprZ3D1DENVUe8E4rgCR4A8J |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbhMxEB5VrVS4QMtPCdDiA-K2kXfXu85yQ6RpG9BSlRR6s7z-EVVKEjUbqeLEI_CMPAkz3iRNEAeEuK208q494_F8Y3-eAXhpEQQnlZFRXFkbiYK7SEvrIoNggXcsp6MlYluU-fG56F9kF3P-E92FafJDLDfcyDLCek0GPrF-3chzuhUt47A1ItoIVsSojXhyS-RpQoFY92yZSiqWaahiyQsuIvLp66yeP35pzVVtkdRviDqppyg935S9WPFbq9g2OKfefRguhtVwUobtWV21zbffMj7-n3HvwL05hmVvmkm3Cxtu9ADudIl3RKXjHsKgyYN-aZjRk6mmw3uG4JihAmkbhn2lun1skSzhNZt-wSDg5_cf5CYYxv-zq3rKxp5pNrm8Gtcs5MB9BOe9w8Hb42heviEyIivKyPhYe9FBQOLiwkmNqne-qFyWatfR3GtvvXEdbnmaxp4iKZEkVicmRYxTYZD_GDZH45F7AiwrtM5zStRjnIi1pqKX2hS42uTWGS5bEC80pSZNlg61Et2gvBTJi2puChXkpW5a8CqodNlAXw-J5SYz9bk8UoPBp49pX3J11oKDNZ3f_oGK4yCcbMFeMwlu3wiJwKrAfuVBlX_dKdX_cIpP5dN_bfgCtk-7PfX-pHz3DO42NCPi3jyHzfp65vYRQdXVQTCNX1EhDbg |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Systemic+capsaicin+for+burning+mouth+syndrome%3A+short-term+results+of+a+pilot+study&rft.jtitle=Journal+of+oral+pathology+%26+medicine&rft.au=PETRUZZI%2C+Massimo&rft.au=LAURITANO%2C+Dorina&rft.au=DE+BENEDITTIS%2C+Michele&rft.au=BALDONI%2C+Marco&rft.date=2004-02-01&rft.pub=Blackwell&rft.issn=0904-2512&rft.eissn=1600-0714&rft.volume=33&rft.issue=2&rft.spage=111&rft.epage=114&rft_id=info:doi/10.1111%2Fj.1600-0714.2004.0194n.x&rft.externalDBID=n%2Fa&rft.externalDocID=15513441 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0904-2512&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0904-2512&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0904-2512&client=summon |